fig1

From: Bilirubin ameliorates metabolic dysregulation by targeting the HSP90β/SREBPs signaling axis to improve insulin resistance and mitigate ectopic lipid deposition

Bilirubin ameliorates metabolic dysregulation by targeting the HSP90β/SREBPs signaling axis to improve insulin resistance and mitigate ectopic lipid deposition

Figure 1. Bilirubin inhibits intracellular lipid accumulation in vitro. (A) Chemical structure of bilirubin; (B and C) Cellular TC (B) and TG (C) contents measured in human liver HL-7702 cells treated with DMSO or Bilirubin (12.5, 25, 50 μM) for 24 h; (D) Cell viability of HL-7702 cells treated with increasing concentrations of bilirubin (12.5-400 μM) for 24 h, assessed by MTT assay; (E) Following fixation, cells were stained with Nile Red to visualize neutral lipids. Quantification of lipid droplets was performed using IPP software based on three independent experiments. Scale bar = 10 μm. IPP: Image-Pro plus; MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TC: total cholesterol; TG: triglyceride. ^*P < 0.05; ^**P < 0.01; ^***P < 0.001 vs. Con.